BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen X, Wang Y, Wu H, Cheng C, Le W. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurol Sci 2020;41:2055-65. [DOI: 10.1007/s10072-020-04333-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim MM, Alshehri S, Mustafa G, Ahmad J, Alhakamy NA, Mishra A. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Front Pharmacol 2022;13:805388. [DOI: 10.3389/fphar.2022.805388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zheng C, Zhang F. New insights into pathogenesis of l-DOPA-induced dyskinesia. Neurotoxicology 2021;86:104-13. [PMID: 34331976 DOI: 10.1016/j.neuro.2021.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Pinna A, Costa G, Serra M, Contu L, Morelli M. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist. Neuropharmacology 2021;196:108693. [PMID: 34229013 DOI: 10.1016/j.neuropharm.2021.108693] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Cacabelos R, Carrera I, Martínez O, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Tellado I, Cacabelos N, Pego R, Naidoo V, Carril JC. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev 2021;41:2841-86. [PMID: 34106485 DOI: 10.1002/med.21838] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Negida A, Ghaith HS, Fala SY, Ahmed H, Bahbah EI, Ebada MA, Aziz MAE. Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis. Neurol Sci 2021;42:3135-43. [PMID: 34014397 DOI: 10.1007/s10072-021-05319-7] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Fabbrini A, Guerra A. Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia. J Exp Pharmacol 2021;13:469-85. [PMID: 33953618 DOI: 10.2147/JEP.S265282] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Li L, Cheng L, Wang Y. Differential roles of two isoforms of dopamine D2 receptors in l-dopa-induced abnormal involuntary movements in mice. Neuroreport 2021;32:555-61. [PMID: 33850083 DOI: 10.1097/WNR.0000000000001623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Dev Res 2021;82:695-706. [PMID: 33458869 DOI: 10.1002/ddr.21784] [Reference Citation Analysis]